 |
|
Hemolytic Uremic Syndrome Associated With Clopidogrel
A Case Report
Beverly Moy, MD;
John C. Wang, MD;
Glen D. Raffel, MD;
J. Paul Marcoux II, MD
Arch Intern Med. 2000;160:1370-1372.
Clopidogrel and ticlopidine are antiplatelet agents used in the treatment of patients with cerebrovascular and peripheral vascular disease and to reduce the risk for thrombosis in patients undergoing coronary artery stenting. Ticlopidine has been reported to have major hematologic adverse effects, including neutropenia and thrombotic thrombocytopenic purpura or hemolytic uremic syndrome (HUS). Clopidogrel, an analogue of ticlopidine, was developed because it did not show bone marrow toxic effects in either tissue culture or animal models. In human studies, to date, clopidogrel has been associated with a low incidence of severe neutropenia and no reported cases of thrombotic thrombocytopenic purpura or HUS. For these reasons, clopidogrel has been increasingly used in place of ticlopidine after coronary artery stenting. We report a case of clopidogrel-associated HUS. This observation implicates clopidogrel as a possible causative agent in HUS.
From the Department of Medicine, Brigham and Women's Hospital (Drs Moy and Wang), Department of Medicine, Beth Israel-Deaconess Medical Center (Dr Raffel), Harvard Medical School; and Department of Hematology-Oncology, Harvard Vanguard Medical Associates (Dr Marcoux); Boston, Mass.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Harrington et al.
Chest 2008;133:670S-707S.
ABSTRACT
| FULL TEXT
Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Popma et al.
Chest 2004;126:576S-599S.
ABSTRACT
| FULL TEXT
Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention
Popma et al.
Chest 2001;119:321S-336S.
FULL TEXT
|
